Get the Stockscreener App
111.01
2.54%
2.75
After Hours:
110.70
-0.31
-0.28%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $111.01, with a volume of 11.96M.
It is up +2.54% in the last 24 hours and up +10.68% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$108.26
Open:
$108.97
24h Volume:
11.96M
Relative Volume:
0.90
Market Cap:
$275.53B
Revenue:
$63.90B
Net Income/Loss:
$19.05B
P/E Ratio:
14.68
EPS:
7.5596
Net Cash Flow:
$13.05B
1W Performance:
+2.22%
1M Performance:
+10.68%
6M Performance:
+32.68%
1Y Performance:
+11.40%
1-Day Range:
$107.95
$111.22
1-Week Range:
$107.22
$112.90
52-Week Range:
$73.31
$112.90
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
111.01 | 268.70B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
LLY
Lilly Eli Co
|
1,073.29 | 964.11B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.55 | 514.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
221.89 | 390.15B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
146.16 | 271.72B | 54.45B | 14.42B | 17.15B | 7.333 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings - TechStock²
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Merck & Co., Inc. (NYSE:MRK) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Trading Up 2.4%Should You Buy? - MarketBeat
Manning & Napier Advisors LLC Has $15.67 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Kera Capital Partners Inc. Buys 9,382 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case - Chartmill
Eastern Bank Sells 47,755 Shares of Merck & Co., Inc. $MRK - MarketBeat
Is Merck & Co Inc Gaining or Losing Market Support? - Benzinga
J.P. Morgan: Revolution Awaits Key Readout As Merck Takeover Rumors Swirl - Citeline News & Insights
Nordea Investment Management AB Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by S Bank Fund Management Ltd - MarketBeat
RWC Asset Management LLP Has $18.42 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
MGO One Seven LLC Increases Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Trading Down 1.2%Here's Why - MarketBeat
Merck Wants to Do More Multi Tens of Billion-Dollar Deals - Bloomberg.com
Merck says new growth opportunities to drive revenue of $70 billion by mid-2030s - Reuters
AirNexis Launches To Take On Merck In Expanding PDE3/4i COPD Field - Citeline News & Insights
Merck & Co., Inc. $MRK Shares Sold by Tokio Marine Asset Management Co. Ltd. - MarketBeat
Sumitomo Mitsui Trust Group Inc. Decreases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Tema Etfs LLC Acquires 39,849 Shares of Merck & Co., Inc. $MRK - MarketBeat
Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $31.72 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Godsey & Gibb Inc. - MarketBeat
MRK Stock Price, Forecast & Analysis | MERCK & CO. INC. (NYSE:MRK) - Chartmill
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch - TechStock²
New York State Teachers Retirement System Lowers Stock Position in Merck & Co., Inc. $MRK - MarketBeat
MRK Stock Price and Chart — NYSE:MRK - TradingView — Track All Markets
Key deals this week: Merck, Glencore, CrowdStrike, Marvell Technology, Steel Dynamics and more - Seeking Alpha
Merck & Co., Inc. $MRK Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
Narwhal Capital Management Reduces Holdings in Merck & Co., Inc. $MRK - MarketBeat
Eikon Therapeutics Files for IPO Led By Merck Veterans - Bloomberg.com
Merck in Talks to Buy Revolution Medicines Per Financial Times Report - Finviz
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play - TechStock²
Oregon Public Employees Retirement Fund Buys 68,594 Shares of Merck & Co., Inc. $MRK - MarketBeat
Nisa Investment Advisors LLC Sells 125,886 Shares of Merck & Co., Inc. $MRK - MarketBeat
Next Level Private LLC Lowers Position in Merck & Co., Inc. $MRK - MarketBeat
Park Avenue Securities LLC Acquires 18,839 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck in Talks to Buy Biotech Revolution Medicines, FT Says - Bloomberg.com
Merck reportedly consiering a major acquisition (Revolution Medicines) - marketscreener.com
Merck & Co., Inc. $MRK Shares Acquired by Capital Investment Advisors LLC - MarketBeat
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight - Benzinga
Where is Merck & Co. (MRK) headed according to Wall Street? - MSN
Wells Fargo adds Merck (MRK) to Q1 2026 tactical list ahead of key catalysts - MSN
Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts - Finviz
Merck urges science-led US vaccine schedule after CDC trims childhood vaccine list - Reuters
Merck & Co., Inc. (NYSE:MRK) Shares Up 2.1% Following Analyst Upgrade - MarketBeat
Merck might buy Revolution Medicines - breakingthenews.net
Merck upgraded, AbbVie downgraded at Wolfe (MRK:NYSE) - Seeking Alpha
Why Merck (MRK) is a Top Growth Stock for the Long-Term - Yahoo Finance Singapore
Merck & Co., Inc. (NYSE:MRK) Stock Rating Upgraded by Wolfe Research - MarketBeat
United Asset Strategies Inc. Acquires 21,765 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.21%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):